Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
Enanta Pharmaceuticals, Inc. (ENTA)
Last enanta pharmaceuticals, inc. earnings: 2/6 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.enanta.com/investor-overview
Company Research
Source: Business Wire
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data for EDP-978, the Company’s KIT inhibitor in development for the treatment of mast cell-mediated, Type 2 immune diseases, will be presented in two poster presentations at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting being held February 27 – March 2, 2026 in Philadelphia, PA.Details of the presentations are as follows:Abstract Title: Discovery of a Potent and Selective KIT inhibitor for Treatment of Mast Cell-Mediated DiseasesDate: Friday, February 27, 2026Time: 2:45 – 3:45 PM ESTPoster Number: 104Session: Allergic Skin DiseasesLocation: Convention Center, Level 2, Hall EPresenter: Tessa Cressey, Ph.D.Abstract Title: EDP-978, a Potent KIT Inhibitor, Demonstrated Dose-Dependent Target-Engagement and a Favo
Show less
Read more
Impact Snapshot
Event Time:
ENTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENTA alerts
High impacting Enanta Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ENTA
News
- Enanta Pharmaceuticals (NASDAQ:ENTA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025Business Wire
ENTA
Earnings
- 2/9/26 - Beat
ENTA
Sec Filings
- 2/11/26 - Form S-3
- 2/11/26 - Form 10-Q
- 2/9/26 - Form 8-K
- ENTA's page on the SEC website